Author + information
- Received October 30, 2019
- Revision received February 18, 2020
- Accepted February 25, 2020
- Published online May 18, 2020.
- Troels Thim, MD, PhDa,∗ (, )
- Nina W. van der Hoeven, MDb,
- Carmine Musto, MD, PhDc,
- Robin Nijveldt, MD, PhDd,
- Matthias Götberg, MD, PhDe,
- Thomas Engstrøm, MD, PhDf,
- Pieter C. Smits, MD, PhDg,
- Keith G. Oldroyd, MDh,
- Anthony H. Gershlick, MBBSi,
- Javier Escaned, MD, PhDj,
- Sergio Bravo Baptista, MD, PhDk,
- Luis Raposo, MDl,
- Niels van Royen, MD, PhDd and
- Michael Maeng, MD, PhDa
- aDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark
- bDepartment of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands
- cDepartment of Interventional Cardiology, San Camillo Hospital, Rome, Italy
- dDepartment of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands
- eDepartment of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden
- fDepartment of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- gDepartment of Cardiology, Maasstad Ziekenhuis, Rotterdam, the Netherlands
- hDepartment of Cardiology, Golden Jubilee National Hospital, Glasgow, United Kingdom
- iUniversity of Leicester, University Hospitals of Leicester, Leicester Biomedical Research Unit, Leicester, United Kingdom
- jHospital Clinico San Carlos IDISSC, Complutense University, Madrid, Spain
- kUniversity Clinic of Cardiology, Faculty of Medicine at University of Lisbon, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal
- lCardiology Department, Santa Cruz Hospital–CHLO, Lisbon, Portugal
- ↵∗Address for correspondence:
Dr. Troels Thim, Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.
• CR is beneficial for patients with STEMI.
• Acute physiological changes may affect the acute and subacute evaluation of NCLs.
• Optimal timing of evaluation and revascularization of NCLs remains to be established.
Nonculprit lesions are frequently observed in patients with ST-segment elevation myocardial infarction. Results from recent randomized clinical trials suggest that complete revascularization after ST-segment elevation myocardial infarction improves outcomes. In this state-of-the-art paper, the authors review these trials and consider how best to determine which nonculprit lesions require revascularization and when this should be performed.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.
- Received October 30, 2019.
- Revision received February 18, 2020.
- Accepted February 25, 2020.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.